Paper16487232
Orphan drug development is progressing too slowly.
Joppi R and 2 others. Br J Clin Pharmacol, 2006. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. Orphan drug development is progressing too slowly. Papers, record 16487232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16487232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Industry | Major topic |
| Pharmaceutical Preparations | Major topic |
| Animals | |
| Documentation | |
| European Union | |
| Health Systems Agencies | |
| Research | |
| Retrospective Studies |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 16487216 | Rare diseases and orphan drugs. | https://conductscience.org/library/papers/16487216 |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42185862 | Rare disease patients protection: theoretical discussion and institutional construction of orphan drug designation in China. | Orphanet J Rare Dis | 2026 | https://conductscience.org/library/papers/42185862 | PubMed |
| 38778810 | Pharmaceutical policy and innovation for rare diseases: A narrative review. | F1000Res | 2023 | https://conductscience.org/library/papers/38778810 | PubMed |
| 38523639 | Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38523639 | PubMed |
| 37325577 | Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020]. | Perspect Clin Res | 2023 | https://conductscience.org/library/papers/37325577 | PubMed |
| 34287806 | The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. | Eur J Drug Metab Pharmacokinet | 2021 | https://conductscience.org/library/papers/34287806 | PubMed |
| 31364772 | Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval. | J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/31364772 | PubMed |
| 30400970 | Recommendations for the design of small population clinical trials. | Orphanet J Rare Dis | 2018 | https://conductscience.org/library/papers/30400970 | PubMed |
| 29788976 | Improving the analysis of composite endpoints in rare disease trials. | Orphanet J Rare Dis | 2018 | https://conductscience.org/library/papers/29788976 | PubMed |
| 27600717 | The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. | Orphanet J Rare Dis | 2016 | https://conductscience.org/library/papers/27600717 | PubMed |
| 27301273 | Directions for new developments on statistical design and analysis of small population group trials. | Orphanet J Rare Dis | 2016 | https://conductscience.org/library/papers/27301273 | PubMed |
| 26511061 | Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. | Orphanet J Rare Dis | 2015 | https://conductscience.org/library/papers/26511061 | PubMed |
| 23109143 | Unintended effects of orphan product designation for rare neurological diseases. | Ann Neurol | 2012 | https://conductscience.org/library/papers/23109143 | PubMed |
| 23090701 | Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. | Eur J Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23090701 | PubMed |
| 23040887 | Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. | J Allergy Clin Immunol | 2013 | https://conductscience.org/library/papers/23040887 | PubMed |
| 21892964 | Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe? | Orphanet J Rare Dis | 2011 | https://conductscience.org/library/papers/21892964 | PubMed |
| 21842335 | Time to revisit the orphan drug law. | Eur J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/21842335 | PubMed |
| 21395641 | Access to orphan drugs despite poor quality of clinical evidence. | Br J Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21395641 | PubMed |
| 21073206 | Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. | Pharmacoeconomics | 2011 | https://conductscience.org/library/papers/21073206 | PubMed |
| 20624867 | Policy alternatives for treatments for rare diseases. | CMAJ | 2010 | https://conductscience.org/library/papers/20624867 | PubMed |
| 20082539 | Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. | Drug Saf | 2010 | https://conductscience.org/library/papers/20082539 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16487232
GET https://conductscience.org/api/papers/v1/16487232/cited_by?page=2